DaVita (NYSE:DVA) CFO Sells $9,887,579.10 in Stock

DaVita Inc. (NYSE:DVA) CFO Joel Ackerman sold 51,471 shares of the stock in a transaction on Thursday, May 7th. The stock was sold at an average price of $192.10, for a total transaction of $9,887,579.10. Following the completion of the sale, the chief financial officer directly owned 132,434 shares of the company’s stock, valued at $25,440,571.40. The trade was a 27.99% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link.

DaVita Trading Down 1.2%

Shares of DVA stock opened at $198.08 on Thursday. The company has a market cap of $12.72 billion, a PE ratio of 18.37, a P/E/G ratio of 0.66 and a beta of 0.84. The company’s fifty day simple moving average is $156.68 and its 200-day simple moving average is $134.68. DaVita Inc. has a 52 week low of $101.00 and a 52 week high of $202.69.

DaVita (NYSE:DVA) last announced its quarterly earnings results on Tuesday, May 5th. The company reported $2.87 earnings per share (EPS) for the quarter, beating the consensus estimate of $2.33 by $0.54. DaVita had a negative return on equity of 270.37% and a net margin of 5.65%.The firm had revenue of $3.42 billion during the quarter, compared to the consensus estimate of $3.36 billion. During the same period in the prior year, the firm earned $2.00 EPS. The firm’s quarterly revenue was up 6.0% compared to the same quarter last year. DaVita has set its FY 2026 guidance at 14.100-15.200 EPS. Equities research analysts expect that DaVita Inc. will post 15.07 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

Several research firms recently commented on DVA. Truist Financial boosted their price target on DaVita from $158.00 to $205.00 and gave the stock a “hold” rating in a research report on Friday, May 8th. Barclays lifted their price objective on shares of DaVita from $158.00 to $194.00 and gave the company an “equal weight” rating in a research note on Thursday, May 7th. Deutsche Bank Aktiengesellschaft upgraded shares of DaVita from a “hold” rating to a “buy” rating and upped their target price for the company from $126.00 to $220.00 in a research note on Wednesday, May 6th. Zacks Research raised shares of DaVita from a “hold” rating to a “strong-buy” rating in a research note on Thursday, May 7th. Finally, UBS Group boosted their price objective on shares of DaVita from $190.00 to $235.00 and gave the stock a “buy” rating in a report on Thursday, May 7th. One analyst has rated the stock with a Strong Buy rating, two have issued a Buy rating, four have assigned a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat, DaVita has a consensus rating of “Hold” and a consensus target price of $199.17.

Trending Headlines about DaVita

Here are the key news stories impacting DaVita this week:

• Positive Sentiment: DaVita’s latest quarter beat expectations on both earnings and revenue, with EPS of $2.87 versus $2.33 expected and revenue of $3.42 billion versus $3.36 billion projected. Revenue also rose 6% year over year, supporting the case for improved operating performance. Article Title
• Positive Sentiment: Analysts turned more constructive after earnings: Deutsche Bank upgraded the stock to Buy and raised its target to $220, UBS lifted its target to $235, TD Cowen increased its target to $201, and Barclays raised its target to $194. The average target now sits near $199, suggesting valuation support near current levels. Article Title
• Positive Sentiment: Zacks highlighted DaVita as a strong momentum stock and also included it on its list of Strong Buy growth names, reinforcing the market’s bullish short-term sentiment. Article Title
• Neutral Sentiment: The company presented at the Bank of America Global Healthcare Conference, where management likely reinforced the earnings and operating outlook, but no major new announcement was highlighted in the transcript headline. Article Title
• Negative Sentiment: CFO Joel Ackerman sold 51,471 shares, worth about $9.9 million. While insider selling does not automatically signal trouble, it can create a small overhang for investors near recent highs. Article Title

Institutional Trading of DaVita

A number of hedge funds and other institutional investors have recently made changes to their positions in DVA. Arrowstreet Capital Limited Partnership lifted its position in shares of DaVita by 114.9% during the fourth quarter. Arrowstreet Capital Limited Partnership now owns 1,190,000 shares of the company’s stock worth $135,196,000 after purchasing an additional 636,191 shares during the last quarter. Norges Bank bought a new stake in DaVita in the fourth quarter valued at about $49,164,000. Corient Private Wealth LLC raised its stake in DaVita by 1,493.1% during the fourth quarter. Corient Private Wealth LLC now owns 358,299 shares of the company’s stock valued at $40,706,000 after buying an additional 335,809 shares in the last quarter. Man Group plc raised its stake in DaVita by 1,608.6% during the second quarter. Man Group plc now owns 285,809 shares of the company’s stock valued at $40,713,000 after buying an additional 269,081 shares in the last quarter. Finally, Neuberger Berman Group LLC grew its position in shares of DaVita by 138.5% in the 3rd quarter. Neuberger Berman Group LLC now owns 463,250 shares of the company’s stock worth $61,502,000 after acquiring an additional 269,015 shares in the last quarter. Institutional investors own 90.12% of the company’s stock.

DaVita Company Profile

DaVita Inc (NYSE: DVA) is a leading provider of kidney care services, specializing in the management and operation of outpatient dialysis centers for patients with chronic kidney failure and end-stage renal disease. Headquartered in Denver, Colorado, the company offers a comprehensive suite of treatment modalities, including in-center hemodialysis, peritoneal dialysis, and home dialysis therapies. In addition to its core dialysis services, DaVita provides patient education, nutritional counseling, vascular access management and related laboratory services to support kidney health and overall patient well-being.

Since its formation in the mid-1990s through a clinical management services spin-off, DaVita has expanded both organically and through strategic partnerships and acquisitions.